Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 22

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 22
---
 shares.                                                                                                                              |
| Common stock to be outstanding after this offering |   | 43,642,271 shares (assuming no sale of any Pre-Funded Warrants and assuming none of the Series Warrants issued in this offering are exercised). |

| Use of proceeds |     | We estimate that the net proceeds to us from this offering will be approximately $6.99 million, after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of the Series Warrants. We intend to use the net proceeds from the sale of the securities for working capital and general corporate purposes. See “Use of Proceeds” on page 41 of this prospectus. |

| Risk factors |     | You should carefully read and consider the information set forth under “Risk Factors” on page 12 of this prospectus before deciding to invest in our securities. |

| Lock-up agreements |     | We, and each of our officers and directors have agreed, subject to certain exceptions, not to sell, offer, agree to sell, contract to sell, hypothecate, pledge, grant any option to purchase, make any short sale of, or otherwise dispose of or hedge, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock, for a period of days after the date in which the Warrant Stockholder Approval is obtained, without the prior written consent of Dawson James Securities, Inc. For more information, see “Plan of Distribution” on page 70 of this prospectus. |

| Market for common stock |     | Our common stock is listed on The Nasdaq Capital Market under the symbol “PTPI.” |

10

| Listing of Pre-Funded Warrants and Series Warrants |     | We do not intend to list the Pre-Funded Warrants or either of the Series Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the Pre-Funded Warrants and Series Warrants will be extremely limited. |

The number of shares of our common stock to be outstanding after this offering is based on 11,319,039 shares of our common stock outstanding as of February 13, 2025, and excludes the following:

| ● | 8,106,821 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $13.62 per share; |

| ● | 420,133 shares of common stock underlying outstanding stock options